Health Winners & Losers: Amylin

Health stocks took another beating Wednesday, although the damage wasn't quite as severe as it was in the broader market, as the Nasdaq and Amex biotechnology indices lost roughly 4%.

Among the stocks in the news, drugmaker Wyeth (WYE Quote) said European regulators requested that trials of its experimental Alzheimer's drug bapineuzumab be delayed while they review mid-stage data presented earlier this year.

In July, data from a phase II study showed that patients didn't have a statistically significant benefit from treatment with the drug. Wyeth and its partner Elan (ELN Quote) called the results "encouraging," however, and said the data support the decision to conduct ongoing phase III studies. ...